S&P 500   4,283.94 (+0.38%)
DOW   33,745.60 (+0.24%)
QQQ   352.61 (+1.09%)
AAPL   179.20 (+0.78%)
MSFT   326.04 (+0.82%)
META   266.70 (+1.18%)
GOOGL   123.08 (+0.47%)
AMZN   125.14 (+3.23%)
TSLA   232.33 (+3.46%)
NVDA   385.06 (+2.75%)
NIO   7.66 (-1.29%)
BABA   86.90 (+1.90%)
AMD   121.13 (+2.80%)
T   15.94 (-0.99%)
F   13.47 (-0.88%)
MU   65.07 (-2.97%)
CGC   0.70 (-2.57%)
GE   107.10 (+0.96%)
DIS   92.14 (-0.41%)
AMC   4.59 (-2.96%)
PFE   39.03 (+0.36%)
PYPL   64.53 (+0.77%)
NFLX   406.46 (+1.67%)
S&P 500   4,283.94 (+0.38%)
DOW   33,745.60 (+0.24%)
QQQ   352.61 (+1.09%)
AAPL   179.20 (+0.78%)
MSFT   326.04 (+0.82%)
META   266.70 (+1.18%)
GOOGL   123.08 (+0.47%)
AMZN   125.14 (+3.23%)
TSLA   232.33 (+3.46%)
NVDA   385.06 (+2.75%)
NIO   7.66 (-1.29%)
BABA   86.90 (+1.90%)
AMD   121.13 (+2.80%)
T   15.94 (-0.99%)
F   13.47 (-0.88%)
MU   65.07 (-2.97%)
CGC   0.70 (-2.57%)
GE   107.10 (+0.96%)
DIS   92.14 (-0.41%)
AMC   4.59 (-2.96%)
PFE   39.03 (+0.36%)
PYPL   64.53 (+0.77%)
NFLX   406.46 (+1.67%)
S&P 500   4,283.94 (+0.38%)
DOW   33,745.60 (+0.24%)
QQQ   352.61 (+1.09%)
AAPL   179.20 (+0.78%)
MSFT   326.04 (+0.82%)
META   266.70 (+1.18%)
GOOGL   123.08 (+0.47%)
AMZN   125.14 (+3.23%)
TSLA   232.33 (+3.46%)
NVDA   385.06 (+2.75%)
NIO   7.66 (-1.29%)
BABA   86.90 (+1.90%)
AMD   121.13 (+2.80%)
T   15.94 (-0.99%)
F   13.47 (-0.88%)
MU   65.07 (-2.97%)
CGC   0.70 (-2.57%)
GE   107.10 (+0.96%)
DIS   92.14 (-0.41%)
AMC   4.59 (-2.96%)
PFE   39.03 (+0.36%)
PYPL   64.53 (+0.77%)
NFLX   406.46 (+1.67%)
S&P 500   4,283.94 (+0.38%)
DOW   33,745.60 (+0.24%)
QQQ   352.61 (+1.09%)
AAPL   179.20 (+0.78%)
MSFT   326.04 (+0.82%)
META   266.70 (+1.18%)
GOOGL   123.08 (+0.47%)
AMZN   125.14 (+3.23%)
TSLA   232.33 (+3.46%)
NVDA   385.06 (+2.75%)
NIO   7.66 (-1.29%)
BABA   86.90 (+1.90%)
AMD   121.13 (+2.80%)
T   15.94 (-0.99%)
F   13.47 (-0.88%)
MU   65.07 (-2.97%)
CGC   0.70 (-2.57%)
GE   107.10 (+0.96%)
DIS   92.14 (-0.41%)
AMC   4.59 (-2.96%)
PFE   39.03 (+0.36%)
PYPL   64.53 (+0.77%)
NFLX   406.46 (+1.67%)
NASDAQ:VACC

Vaccitech (VACC) Stock Forecast, Price & News

$2.46
-0.04 (-1.60%)
(As of 10:51 AM ET)
Compare
Today's Range
$2.46
$2.50
50-Day Range
$2.19
$2.51
52-Week Range
$2.02
$7.45
Volume
2,416 shs
Average Volume
49,100 shs
Market Capitalization
$94.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.67

Vaccitech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
412.8% Upside
$12.67 Price Target
Short Interest
Healthy
0.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.84mentions of Vaccitech in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$36,575 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.39) to ($2.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

447th out of 981 stocks

Pharmaceutical Preparations Industry

212th out of 484 stocks


VACC stock logo

About Vaccitech (NASDAQ:VACC) Stock

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

Receive VACC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccitech and its competitors with MarketBeat's FREE daily newsletter.

VACC Stock News Headlines

New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
Vaccitech: Q1 Earnings Insights
New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
Short Interest in Vaccitech plc (NASDAQ:VACC) Declines By 16.6%
Vaccitech Plc (VACC) Gets a Buy from Morgan Stanley
Vaccitech (NASDAQ:VACC) PT Lowered to $15.00
Barclays Trims Vaccitech (NASDAQ:VACC) Target Price to $7.00
See More Headlines

VACC Price History

VACC Company Calendar

Last Earnings
3/24/2023
Today
6/08/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VACC
Fax
N/A
Employees
33
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.67
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+412.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$5.34 million
Pretax Margin
-65.00%

Debt

Sales & Book Value

Annual Sales
$44.70 million
Cash Flow
$0.27 per share
Book Value
$6.52 per share

Miscellaneous

Free Float
36,048,000
Market Cap
$94.72 million
Optionable
Not Optionable
Beta
0.16

Key Executives

  • Mr. William J. Enright MBA (Age 60)
    CEO & Director
    Comp: $916.62k
  • Dr. Margaret Marshall M.D. (Age 66)
    Chief Medical Officer
    Comp: $662.04k
  • Ms. Sarah Gilbert
    Co-Founder
  • Mr. Adrian Hill Ph.D.
    Co-Founder & Scientific Advisor
  • Ms. Gemma Brown (Age 33)
    CFO & Company Sec.
  • Mr. Chris Ellis (Age 63)
    Chief Operating Officer
  • Dr. Nadege Pelletier Ph.D. (Age 45)
    Chief Scientific Officer
  • Mr. Graham  GriffithsMr. Graham Griffiths (Age 44)
    Chief Bus. Officer
  • Ms. Elizabeth Eagling-Vose M.B.A.
    Head of Clinical Operations
  • Bernie McDonald
    Head of IP













VACC Stock - Frequently Asked Questions

Should I buy or sell Vaccitech stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccitech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VACC shares.
View VACC analyst ratings
or view top-rated stocks.

What is Vaccitech's stock price forecast for 2023?

2 brokers have issued 1-year price objectives for Vaccitech's shares. Their VACC share price forecasts range from $7.00 to $16.00. On average, they anticipate the company's share price to reach $12.67 in the next twelve months. This suggests a possible upside of 412.8% from the stock's current price.
View analysts price targets for VACC
or view top-rated stocks among Wall Street analysts.

How have VACC shares performed in 2023?

Vaccitech's stock was trading at $2.35 at the beginning of 2023. Since then, VACC stock has increased by 5.1% and is now trading at $2.47.
View the best growth stocks for 2023 here
.

Are investors shorting Vaccitech?

Vaccitech saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 20,400 shares, an increase of 43.7% from the April 30th total of 14,200 shares. Based on an average daily trading volume, of 52,800 shares, the short-interest ratio is currently 0.4 days. Currently, 0.1% of the company's stock are short sold.
View Vaccitech's Short Interest
.

When is Vaccitech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our VACC earnings forecast
.

How were Vaccitech's earnings last quarter?

Vaccitech plc (NASDAQ:VACC) posted its quarterly earnings results on Friday, March, 24th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.12. The business had revenue of $6.46 million for the quarter, compared to analysts' expectations of $3.07 million. Vaccitech had a negative trailing twelve-month return on equity of 6.33% and a negative net margin of 51.19%.

When did Vaccitech IPO?

(VACC) raised $110 million in an IPO on Friday, April 30th 2021. The company issued 6,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

What is Vaccitech's stock symbol?

Vaccitech trades on the NASDAQ under the ticker symbol "VACC."

Who are Vaccitech's major shareholders?

Vaccitech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Liontrust Investment Partners LLP (1.19%), Ipswich Investment Management Co. Inc. (0.07%) and Renaissance Technologies LLC (0.03%). Insiders that own company stock include Christopher Ellis, Graham Griffiths, Joseph Scheeren, Karen A Dawes, M&G Investment Management Ltd, Robin Wright, Sciences Innovation Plc Oxford and William Enright.
View institutional ownership trends
.

How do I buy shares of Vaccitech?

Shares of VACC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaccitech's stock price today?

One share of VACC stock can currently be purchased for approximately $2.47.

How much money does Vaccitech make?

Vaccitech (NASDAQ:VACC) has a market capitalization of $94.72 million and generates $44.70 million in revenue each year. The company earns $5.34 million in net income (profit) each year or ($0.40) on an earnings per share basis.

How can I contact Vaccitech?

Vaccitech's mailing address is THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE. The official website for the company is www.vaccitech.co.uk. The company can be reached via phone at 44-18-6581-8808 or via email at ir@vaccitech.co.uk..

This page (NASDAQ:VACC) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -